ZA200901364B - Method of treatment of photodermatoses - Google Patents

Method of treatment of photodermatoses

Info

Publication number
ZA200901364B
ZA200901364B ZA200901364A ZA200901364A ZA200901364B ZA 200901364 B ZA200901364 B ZA 200901364B ZA 200901364 A ZA200901364 A ZA 200901364A ZA 200901364 A ZA200901364 A ZA 200901364A ZA 200901364 B ZA200901364 B ZA 200901364B
Authority
ZA
South Africa
Prior art keywords
photodermatoses
treatment
Prior art date
Application number
ZA200901364A
Other languages
English (en)
Inventor
Philippe Wolgen
Original Assignee
Clinuvel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904745A external-priority patent/AU2006904745A0/en
Application filed by Clinuvel Pharmaceuticals Ltd filed Critical Clinuvel Pharmaceuticals Ltd
Publication of ZA200901364B publication Critical patent/ZA200901364B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200901364A 2006-08-31 2007-08-31 Method of treatment of photodermatoses ZA200901364B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904745A AU2006904745A0 (en) 2006-08-31 Method for Treatment of Photodermatoses
AU2007900862A AU2007900862A0 (en) 2007-02-21 Method for treatment of photodermatoses

Publications (1)

Publication Number Publication Date
ZA200901364B true ZA200901364B (en) 2010-06-30

Family

ID=39135428

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901364A ZA200901364B (en) 2006-08-31 2007-08-31 Method of treatment of photodermatoses

Country Status (16)

Country Link
US (1) US8334265B2 (fr)
EP (2) EP2865422B1 (fr)
AU (1) AU2007291886B2 (fr)
CA (1) CA2662163C (fr)
CY (1) CY1115804T1 (fr)
DK (2) DK2865422T3 (fr)
ES (2) ES2646049T3 (fr)
HU (2) HUE035074T2 (fr)
LU (1) LUC00062I2 (fr)
NL (1) NL300926I2 (fr)
NZ (1) NZ575133A (fr)
PL (2) PL2056855T3 (fr)
PT (2) PT2865422T (fr)
SI (2) SI2865422T1 (fr)
WO (1) WO2008025094A1 (fr)
ZA (1) ZA200901364B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025074A1 (fr) * 2006-08-28 2008-03-06 Clinuvel Pharmaceuticals Limited Méthode destinée à réduire l'incidence ou la vitesse de développement de cancers de la peau et de pathologies associées
CA2716509A1 (fr) * 2008-02-22 2009-08-27 Clinuvel Pharmaceuticals Limited Procede de traitement de la photosensibilite et de la phototoxicite
DK2957292T3 (en) 2008-03-27 2018-01-22 Clinuvel Pharmaceuticals Ltd VITILIGOTERAPHY
CA2761607C (fr) 2009-06-08 2018-09-04 Yi-Qun Shi Peptides specifiques du recepteur de la melanocortine
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
EP2487185A1 (fr) * 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide ayant une activité améliorée pour la réparation de l'ADN cellulaire de cellules dermiques
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
WO2014198890A1 (fr) * 2013-06-13 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de la protoporphyrie érythropoïétique
WO2015063099A1 (fr) * 2013-10-28 2015-05-07 Clinuvel Ag Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey
WO2015063102A1 (fr) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh pour une utilisation dans le traitement de la maladie de hailey-hailey
EP3088417A1 (fr) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Composé pharmaceutique
EP3088418A1 (fr) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Composé pharmaceutique
ES2985745T3 (es) * 2017-02-01 2024-11-07 Vallaurix Mc S A R L Análogos de alfa-MSH utilizados en el tratamiento de Xeroderma Pigmentosum
CA3186880A1 (fr) 2020-06-10 2021-12-16 Mitsubishi Tanabe Pharma Corporation Agent prophylactique ou therapeutique de traitement de la porphyrie
KR20230016008A (ko) 2020-06-10 2023-01-31 미쓰비시 타나베 파마 코퍼레이션 광선성 피부질환의 예방 또는 치료제
WO2021251450A1 (fr) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 Agent prophylactique ou thérapeutique de traitement de la porphyrie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP0979101B1 (fr) 1996-07-03 2010-10-27 Merial, Inc. ADENOVIRUS CANIN 2 RECOMBINANT (ACR2) CONTENANT DE l'ADN EXOGENE
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
IL139637A0 (en) 1998-05-15 2002-02-10 Quark Biotech Inc Mechanical stress induced genes, expression products therefrom, and uses thereof
AU2003206496B2 (en) 2002-02-26 2007-08-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method of stimulation of melanin production and induction of skin tanning
NZ582130A (en) * 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
CA2582607C (fr) * 2004-10-08 2016-07-12 Clinuvel Pharmaceuticals Limited Preparations et methodes permettant d'induire la melanogenese chez un sujet
WO2008025074A1 (fr) 2006-08-28 2008-03-06 Clinuvel Pharmaceuticals Limited Méthode destinée à réduire l'incidence ou la vitesse de développement de cancers de la peau et de pathologies associées

Also Published As

Publication number Publication date
WO2008025094A1 (fr) 2008-03-06
CA2662163C (fr) 2015-11-24
US8334265B2 (en) 2012-12-18
US20100120668A1 (en) 2010-05-13
NL300926I2 (nl) 2018-03-20
LUC00062I1 (fr) 2018-02-08
EP2056855A1 (fr) 2009-05-13
PT2056855E (pt) 2014-12-12
EP2056855A4 (fr) 2013-06-19
AU2007291886B2 (en) 2013-01-10
SI2865422T1 (sl) 2017-12-29
AU2007291886A1 (en) 2008-03-06
ES2646049T3 (es) 2017-12-11
EP2056855B1 (fr) 2014-09-17
ES2525476T3 (es) 2014-12-23
PL2865422T3 (pl) 2018-01-31
EP2865422B1 (fr) 2017-10-18
PL2056855T3 (pl) 2015-04-30
DK2865422T3 (da) 2017-11-20
HUE035074T2 (en) 2018-05-02
CA2662163A1 (fr) 2008-03-06
HK1130208A1 (en) 2009-12-24
PT2865422T (pt) 2017-11-14
EP2865422A1 (fr) 2015-04-29
HUS1800006I1 (hu) 2018-05-02
SI2056855T1 (sl) 2015-01-30
LUC00062I2 (fr) 2018-03-28
DK2056855T3 (en) 2014-12-15
CY1115804T1 (el) 2017-01-25
NZ575133A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
ZA200901364B (en) Method of treatment of photodermatoses
EP2032131A4 (fr) Procédé de traitement
IL193460A0 (en) Compounds and methods for treatment of stroke
IL192555A0 (en) Method of treating multiple sclerosis
ZA200806349B (en) Method for treatment of neuropathic pain
ZA200907349B (en) Method of treating hair
EP2011767A4 (fr) Procédé de traitement d'eau
GB0605360D0 (en) Method of manufacture
GB0718684D0 (en) Treatment method
GB0610746D0 (en) Method of treatment
EP2144886A4 (fr) Méthode de traitement du mélanome
VN25747A1 (en) Method of water treatment
GB0608190D0 (en) Method of purification
GB0725348D0 (en) Method of authentication
IL202002A0 (en) Method of treating diabetes
EP2164494A4 (fr) Procédés de traitement
EP2194793A4 (fr) Procede de traitement de fruits et legumes frais
EP2094385A4 (fr) Procédé de traitement des eaux usagées
EP2203432A4 (fr) Procédé de traitement
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0618227D0 (en) Novel method of treatment
AU2006904745A0 (en) Method for Treatment of Photodermatoses
GB0717337D0 (en) Method of treatment
AU2007900862A0 (en) Method for treatment of photodermatoses
GB0522330D0 (en) Method of treatment